Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin

Article Page

Abstract

A meeting entitled ‘Current Perspective on the Use of Statins in the Treatment of Dyslipidemic Patients’ was held in Stresa, Italy, on 27–28th June 2019. The presentations covered the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines on dyslipidaemia, with discussion about the importance of controlling low-density lipoprotein cholesterol (LDL-C) and the pharmacological opportunities to reach the novel lipid goals. The roles of statins to manage dyslipidaemia in patients with different cardiovascular risks were also discussed. In particular, the efficacy and safety of pitavastatin for the treatment of dyslipidaemia were reviewed, highlighting its further advantages beyond LDL-C reduction. Therefore, the impact of statins on the glycaemic profile was discussed in view of the null/lower effect of pitavastatin as compared with other statins, as well as the interaction profile with other drugs commonly used. This meeting report summarizes the main messages of the discussion with a special focus on pitavastatin, whose main features in different settings are described.

Keywords: cardiovascular risk, diabetes, lipid, low-density lipoprotein, pitavastatin, statin.

Citation: Tokgözoglu L, Zamorano JL. Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin. Drugs in Context 2020; 9: 2020-4-4. DOI: 10.7573/dic.2020-4-4

Contributions: Both authors contributed equally to the preparation of this report. Both named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: JZ received speaker fees from Pfizer, Recordati, Amgen and Sanofi. LT is consultant for Abbott, Amgen, Bayer, MSD, Mylan and Sanofi; she has served as a speaker for Abbott, Actelion, Amgen, Astra, Bayer, MSD, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer and Recordati. She also declares her participation in an Amgen trial; she received honoraria from Daiichi Sankyo. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/05/dic.2020-4-4-COI.pdf

Acknowledgements: The authors thank Content Ed Net (Rome, Italy) for their editorial assistance, with the helpful contribution of Elisa Sala, PhD, medical writer, in drafting the text and Mr Bilal Bham and Hussein Hijazi in the final reading of the manuscript for English language improvement.

Funding declaration: The meeting ‘Current Perspective on the Use of Statins in the Treatment of Dyslipidemic Patients’ was held in Stresa, Italy, on 27–28th June 2019. It was endorsed by EAS and supported by an unrestricted grant from Recordati (Milan, Italy). The authors thank Recordati (Milan, Italy) for an unrestricted grant for editorial assistance.

Copyright: Copyright © 2020 Tokgözoglu L, Zamorano JL. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Tokgözoglu L, Zamorano JL. https://doi.org/10.7573/dic.2020-4-4. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/current-perspectives-on-the-use-of-statins-in-the-treatment-of-dyslipidaemic-patients:-focus-on-pitavastatin

Correspondence: José Luis Zamorano, University Hospital Ramon y Cajal, M-607, km. 9, 100, 28034 Madrid, Spain. zamorano@secardiologia.es

Provenance: submitted; externally peer reviewed.

Submitted: 9 April 2020; Peer review comments to author: 29 April 2020; Revised manuscript received: 18 May 2020; Accepted: 20 May 2020; Publication date: 12 June 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights, and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF